1. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer
   Roberto Filippi et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
2. Medical treatment for cholangiocarcinoma
   Jorge Adeva et al, 2019, Liver Int CrossRef
3. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives
   Roberto Filippi et al, 2019, Expert Opinion on Pharmacotherapy CrossRef
4. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer
   Hidehiro Tajima et al, 2018, mol clin onc CrossRef
5. Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
   Amol Patel et al, 2020, Indian J Med Res CrossRef
6. What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer?
   Haidar ElDarsa et al, 2021, Expert Opinion on Pharmacotherapy CrossRef
7. Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
   Annamaria Massa et al, 2022, Front. Oncol. CrossRef
8. Real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and laboratory parameters in patients across metastatic tumor sites
   Vikas Talreja et al, 2024, IJMIO CrossRef